Geneva, May 28 -- International Clinical Trials Registry received information related to the study (NCT06973096) titled 'CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy' on May 1.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: University of Pennsylvania

Condition: Glioblastoma

Intervention: Drug: CART-EGFR-IL13Ra2 cells...

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: June 2025

Target Sample Size: 9

To know more, visit https://clinicaltrials.gov/ct2/show/NCT06973096

Published by HT Digital Content Services with permission from Healt...